Wattiez Anne-Sophie, Wang Mengya, Russo Andrew F
Department of Molecular Physiology and Biophysics, University of Iowa, Iowa City, IA, USA.
Center for the Prevention and Treatment of Visual Loss, Iowa VA Health Care System, Iowa City, IA, USA.
Handb Exp Pharmacol. 2019;255:85-107. doi: 10.1007/164_2018_187.
With the approval of calcitonin gene-related peptide (CGRP) and CGRP receptor monoclonal antibodies by the Federal Drug Administration, a new era in the treatment of migraine patients is beginning. However, there are still many unknowns in terms of CGRP mechanisms of action that need to be elucidated to allow new advances in migraine therapies. CGRP has been studied both clinically and preclinically since its discovery. Here we review some of the preclinical data regarding CGRP in animal models of migraine.
随着降钙素基因相关肽（CGRP）及CGRP受体单克隆抗体获得美国食品药品监督管理局的批准，偏头痛患者的治疗开启了新纪元。然而，在CGRP的作用机制方面仍有许多未知之处有待阐明，以便在偏头痛治疗上取得新进展。自CGRP被发现以来，已开展了临床和临床前研究。在此，我们综述一些在偏头痛动物模型中有关CGRP的临床前数据。
